Treatment of early rheumatoid arthritis

Modern Rheumatology

Volumn 15, Issue 3, 2005, Pages 153-162

  Fleischmann, Roy M ^a   Stern, Richard L ^a   Iqbal, Imran ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adalimumab; Anti tumor necrosis factor; Combination therapy; Disease modifying antirheumatic drugs (DMARD); Early rheumatoid arthritis; Etanercept; Infliximab; Methotrexate

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

BONE EROSION; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; GOLD THERAPY; HUMAN; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; STATISTICAL SIGNIFICANCE;

EID: 22144473365     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-005-0383-0     Document Type: Review

References (74)

1. MacGregor A, Silman AJ. Rheumatology. 3rd ed. Phildelphia: Elsevier Science; 2003.
2. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline. Arthritis Rheum 1999;42(6):1209-18.
3. Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000;42(6):588-96.
4. Albers JM, Kuper HH, Van Riel PL, Prevoo ML, van't Hof MA, van Gestel AM et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 1999;38(5):423-30.
5. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000;39(6):603-11.
6. Young A, Dixey J, Kulinskaya E, Cox N, Davies P, Devlin J et al. Which patients stop working because of rheumatoid arthritis? Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002;61(4):335-40.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24.
8. van der Horst-Bruinsma IE, Speyer I, Visser H, Breedveld FC, Hazes JM. Diagnosis and course of early-onset arthritis: Results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998;37(10):1084-8.
9. Young A. Short-term outcomes in recent-onset rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:79-86.
10. Chehata JC, Hassell AB, Clarke SA, Mattey DL, Jones MA, Jones PW et al. Mortality in rheumatoid arthritis: Relationship to single and composite measures of disease activity. Rheumatology (Oxford) 2001;40(4):447-52.
11. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM et al. Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48(1):54-8.
12. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16(5):585-91.
13. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression. Arthritis Rheum 1998;41(9):1571-82.
14. Hulsmans HM, Jacobs JW, van der Heijde DM, van Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43(9):1927-40.
15. van der Heijde DM, Van Leeuwen MA, Van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995;22(9):1792-96.
16. Bukhari MA, Wiles NJ, Lunt M, Harrison JB, Scott DG, Symmons DP et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. Arthritis Rheum 2003; 48(1):46-53.
17. Stenger AA, Van Leeuwen MA, Houtman PM, Bruyn GA, Specrsra F, Barendsen BC et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37(11):1157-63.
18. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004;43(7):906-14.
19. van Aken J, Lard LR, Le CS, Hazes JM, Breedveld FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004;63(3):274-9.
20. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: Specificity, sensitivity and diagnostic value. Arthritis Res 2002;4(2):87-93.
21. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43(1):155-63.
22. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt RJ, de Koning MH, Dijkmans BA. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003;30(8):1691-5.
23. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 2004;50(3):709-15.
24. Devlin J, Gough A, Huissoon A, Perkins P, Holder R, Reece R et al. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 1997;24(1):9-13.
25. Dixey J, Solymossy C, Young A. Is it possible to predict radiological damage in early rheumatoid arthritis (RA)? A report on the occurrence, progression, and prognostic factors of radiological erosions over the first 3 years in 866 patients from the Early RA Study (ERAS). J Rheumatol Suppl 2004;69:48-54.
26. Kirwan JR. Links between radiological change, disability, and pathology in rheumatoid arthritis. J Rheumatol 2001;28(4):881-6.
27. Benton N, Stewart N, Crabbe J, Robinson E, Yeoman S, McQueen FM. MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years. Ann Rheum Dis 2004;63(5): 555-61.
28. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998;57(6):350-6.
29. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999;58(3):156-63.
30. McQueen FM, Benton N, Crabbe J, Robinson E, Yeoman S, McLean L et al. What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first 2 years of disease. Ann Rheum Dis 2001;60(9):859-68.
31. Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marster PA et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004;50(4):1107-16.
32. Ostergaard M, Wiell C. Ultrasonography in rheumatoid arthritis: A very promising method still needing more validation. Curr Opin Rheumatol 2004;16(3):223-30.
33. Rau R, Simianer S, Van Riel PL, van de Putte LB, Kruger K, Schattenkirchner M et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J Rheumatol 2004;33(3):145-53.
34. McQueen F, Lassere M, Edmonds J, Conaghan P, Peterfy C, Bird P et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module. J Rheumatol 2003;30(6):1387-92.
35. Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B et al. OMERACT Rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003;30(6):1385-6.
36. Backhaus M, Burmester GR, Sandrock D, Loreck D, Hess D, Scholz A et al. Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints. Ann Rheum Dis 2002;61(10):895-904.
37. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence? Rheumatology (Oxford) 2001;40(11):1211-20.
38. Goldbach-Mansky R, Lipsky PE. New concepts in the treatment of rheumatoid arthritis. Annu Rev Med 2003;54:197-216.
39. Quinn MA, Green MJ, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum 2003; 48(11):3039-45.
40. Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazcs JM et al. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum 2002;46(4):899-905.
41. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: Comparison of two cohorts who received different treatment strategies. Am J Med 2001;111(6):446-51.
42. van der Heijde DM. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996;10(3):435-53.
43. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23(2):137-45.
44. van der Heijde DM, van't Hof M, Van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20(3):579-81.
45. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999;353(9164): 1568-73.
46. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46(4):894-8.
47. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24(10): 1308-15.
48. Larse A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977;18(4):481-91.
49. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350(9074):309-18.
50. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46(2): 347-56.
51. Tugwell P, Bombardier C, Buchanan WW, Goldsmith CH, Grace E, Hanna B. The MACTAR Patient Preference Disability Questionnaire - an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol 1987;14(3):446-51.
52. Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000;43(8):1809-19.
53. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24(10): 1308-15.
54. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38(1):44-8.
55. Drosos AA, Voulgari PV, Katsaraki A, Zikou AK. Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: A 42-month prospective study. Rheumatol Int 2000;19(3):113-8.
56. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004;364(9430):263-9.
57. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39(1):34-40.
58. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343(22):1586-93.
59. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46(6):1443-50.
60. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86.
61. Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: Improvement in disability. J Rheumatol 2004;31(8):1532-7.
62. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van Zeben D, Kerstens PJS, Hazes JM, Zwinderman AH. Treatment strategies in early rheumatoid arthritis: Clinical and radiological outcomes after 2 year follow-up of the BeST study (abstract). Proceedings of the American College of Rheumatology, San Antonio, USA; 2004.
63. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004;50(11):3432-43.
64. Breedveld FC, Kavanaugh A, Cohen SB. Early treatment of rheumatoid arthritis (RA) with adalimumab (Humira) plus methotrexate vs. adalimumab alone or methotrexate alone: The PREMIER Study (abstract). Proceedings of the American College of Rheumatology, San Antonio, USA; 2004.
65. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: What it is and what it isn't. BMJ 1996;312(7023):71-2.
66. Sackett DL. The competing objectives of randomized trials. N Engl J Med 1980;303(18):1059-60.
67. Pincus T, Sokka T. Clinical trials in rheumatic diseases: Designs and limitations. Rheum Dis Clin North Am 2004;30(4):701-24, v-vi.
68. Pincus T, Sokka T. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004;63 (Suppl 2):ii32-9.
69. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003;48(2):313-8.
70. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission. J Rheumatol 2003;30(6):1138-46.
71. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61(4):290-7.
72. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: A study of 1141 patients. J Rheumatol 1993;20(12):2005-9.
73. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br J Rheumatol 1993;32(2):97-103.
74. Kim JM, Weisman MH. When does rheumatoid arthritis begin and why do we need to know? Arthritis Rheum 2000;43(3):473-84.